Lantern Pharma Inc.
Index- P/E- EPS (ttm)-1.47 Insider Own18.70% Shs Outstand10.83M Perf Week-3.21%
Market Cap51.71M Forward P/E- EPS next Y-2.16 Insider Trans-0.68% Shs Float8.80M Perf Month-8.57%
Income-16.20M PEG- EPS next Q-0.54 Inst Own30.40% Short Float1.02% Perf Quarter-10.18%
Sales- P/S- EPS this Y-19.40% Inst Trans-0.97% Short Ratio2.39 Perf Half Y-11.80%
Book/sh5.64 P/B0.91 EPS next Y-19.10% ROA-22.60% Target Price31.00 Perf Year-64.22%
Cash/sh6.16 P/C0.83 EPS next 5Y- ROE-23.70% 52W Range4.76 - 14.20 Perf YTD-35.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.79% Beta-
Dividend %- Quick Ratio12.40 Sales past 5Y- Gross Margin- 52W Low11.02% ATR0.31
Employees14 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)46.27 Volatility6.27% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-100.20% Profit Margin- Rel Volume0.17 Prev Close5.12
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume37.39K Price5.28
Recom2.00 SMA20-6.82% SMA50-4.27% SMA200-17.07% Volume1,207 Change3.21%
Oct-07-21Initiated H.C. Wainwright Buy $32
Aug-30-22 09:00AM  
Aug-19-22 08:30AM  
Aug-09-22 08:20AM  
Aug-08-22 04:01PM  
Aug-01-22 07:00AM  
Jul-14-22 07:00AM  
May-12-22 07:00AM  
May-06-22 10:29AM  
May-05-22 08:00AM  
May-03-22 04:01PM  
Apr-26-22 07:15AM  
Apr-22-22 07:00AM  
Apr-14-22 11:10AM  
Mar-22-22 07:00AM  
Mar-14-22 07:00AM  
Mar-10-22 04:05PM  
Mar-03-22 07:00AM  
Feb-15-22 06:59AM  
Feb-02-22 05:38PM  
Jan-26-22 04:30PM  
Jan-24-22 07:00AM  
Jan-20-22 08:04AM  
Jan-18-22 06:30AM  
Jan-12-22 06:03AM  
Jan-04-22 09:29AM  
Dec-14-21 09:01AM  
Nov-22-21 09:00AM  
Nov-12-21 09:40AM  
Nov-11-21 09:15AM  
Nov-09-21 09:00AM  
Nov-08-21 08:44AM  
Nov-04-21 09:37AM  
Nov-03-21 09:41AM  
Nov-01-21 04:05PM  
Oct-27-21 09:05AM  
Oct-25-21 04:57PM  
Oct-04-21 04:30PM  
Sep-30-21 09:00AM  
Sep-28-21 09:20AM  
Sep-22-21 09:00AM  
Sep-07-21 09:00AM  
Sep-02-21 08:59AM  
Aug-30-21 08:59AM  
Aug-19-21 03:15PM  
Aug-16-21 08:20AM  
Aug-11-21 08:21AM  
Aug-09-21 05:42AM  
Aug-05-21 06:21AM  
Jul-29-21 04:01PM  
Jul-27-21 08:00AM  
Jul-22-21 04:08PM  
Jul-20-21 08:12AM  
Jun-13-21 10:30PM  
May-25-21 08:14AM  
May-17-21 08:55AM  
May-12-21 07:45AM  
May-10-21 06:35AM  
May-03-21 04:32PM  
Apr-29-21 07:00AM  
Apr-26-21 04:30PM  
Apr-06-21 07:45AM  
Apr-01-21 07:59AM  
Mar-25-21 02:45PM  
Mar-23-21 07:48AM  
Mar-22-21 09:10AM  
Mar-17-21 07:00AM  
Mar-12-21 09:00AM  
Mar-11-21 03:21AM  
Mar-10-21 04:00PM  
Mar-03-21 07:00AM  
Feb-22-21 08:52AM  
Feb-16-21 06:35AM  
Jan-20-21 04:00PM  
Jan-14-21 09:30PM  
Jan-06-21 04:20AM  
Jan-04-21 07:00AM  
Dec-17-20 07:00AM  
Dec-15-20 07:00AM  
Dec-11-20 02:32AM  
Dec-08-20 08:32AM  
Nov-24-20 09:30AM  
Nov-10-20 04:53AM  
Oct-29-20 03:59PM  
Oct-22-20 07:00AM  
Oct-19-20 11:35AM  
Oct-05-20 07:46AM  
Sep-22-20 07:55AM  
Sep-11-20 11:46AM  
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kreis Leslie W.10% OwnerSep 02Sale5.206,44533,51420,930Sep 07 04:54 PM
Fletcher Aaron G.L.10% OwnerSep 02Sale5.206,44533,51420,930Sep 07 04:55 PM